Author

Fabrizio Chiodo

Istituto di Chimica BiomolecolareORCID 0000-0003-3619-9982Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Georgia ClaytoniD· 2 shared Magalí B. CoccimiglioiD· 2 shared Tanja D. de GruijliD· 2 shared Yvette van KooykiD· 2 shared Babet O. Springer· 1 shared Christian BlankiD· 1 shared Eelco D. KeuningiD· 1 shared Eleonora NardiniiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Georgia ClaytonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologyiSciencePeer-reviewedAug 25, 2026

Reducing sialylation in melanoma increases classical pathway-mediated complement activation

Magalí B. Coccimiglio, Georgia Clayton, Elisa C. Toffoli…·Yvette van Kooyk

This study shows that reducing sialylation in melanoma enhances classical pathway-mediated complement activation, increasing C3 opsonization and membrane attack complex formation.

DOI 10.1016/j.isci.2026.117326

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 29, 2026

CMAS dampens anti-tumor immunity and associates with response to neoadjuvant immunotherapy in melanoma

Magalí B. Coccimiglio, Sofia Ibáñez‐Molero, Babet O. Springer…·Yvette van Kooyk

The paper shows CMAS in melanoma cells correlates with poor survival and reduced response to immunotherapy by altering tumor-immune interactions.

DOI 10.64898/2026.04.27.719251

mousescRNA-seq

𝕏 PostBluesky